[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505230":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":49,"id":53,"slug":20,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":20,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":20,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"deucravacitinib treatment","EXPERIMENTAL","treatment with deucravacitinib for 6 months",[13],"Drug: deucravacitinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","deucravacitinib","Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Raymond Cho, MD, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","415 575 0524","rashes@ucsf.edu",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","San Francisco","California","94115","United States",{"type":38,"coordinates":39},"Point",[40,41],-122.41942,37.77493,{"lat":41,"lon":40},[44],{"name":45,"role":27,"phone":46,"phoneExt":20,"email":29},"Ray Cho, MD, PhD","415-575-0524",{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[50],{"name":51,"class":52},"Bristol-Myers Squibb","INDUSTRY","100505230",false,"NCT05858645","Correction of Psoriatic T Cell Signatures by Deucravacitinib","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Patients with moderate-severe psoriasis (BSA \\>= 10%, PASI \\>=12, static Physician's Global Assessment (sPGA) 3 and above)\n\nExclusion Criteria:\n\n1. taking systemic immunosuppressives in the last 12 weeks\n2. pregnancy\n3. severe immunodeficiency (either from genetic or infectious causes).\n4. tuberculosis or other active serious infection\n5. active systemic malignancy.\n6. breast-feeding\n7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.","ALL","18 Years","75 Years",{"count":62,"type":63},25,"ESTIMATED","INTERVENTIONAL",[66],"PHASE4","This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.",[69],"Psoriasis Vulgaris","2026-06-01",{"date":72,"type":73},"2026-06-04","ACTUAL",{"date":75,"type":73},"2023-10-01",{"date":77,"type":63},"2028-06",{"name":5,"class":6},1]